{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:48Z","timestamp":1792785048791,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The U.S. Food and Drug Administration","id":[{"id":"https:\/\/ror.org\/034xvzb47","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clavulanic acid, a \u03b2-lactamase inhibitor, is widely co-administered with amoxicillin (as in\n                    <jats:italic>Augmentin<\/jats:italic>\n                    ) to treat a broad range of mild-to-moderate bacterial infections by inhibiting \u03b2-lactamase enzymes produced by resistant bacterial strains. Despite its therapeutic efficacy, clavulanic acid has been associated with drug-induced liver injury, but the underlying mechanisms for this toxicity remain poorly understood. We investigated the contribution of cytochrome P450 (CYP)-mediated metabolism in relation to clavulanic acid-induced cytotoxicity. A panel of TK6-derived cell lines overexpressing 18 individual CYP isoforms (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) was employed. Cells were incubated for 24 and 48 h with freshly prepared clavulanic acid (20-1000 \u00b5M) in RPMI-1640 medium, and the half-maximal inhibitory concentration (IC\u2085\u2080) was determined. Cell growth was more markedly delayed after 48 h of treatment than after 24 h of exposure. Following 48 h of treatment, 13 CYP-overexpressing cell lines showed reduced IC\u2085\u2080 values compared with parental TK6 and TK6\/vector control cells. The rank order was CYP3A4 \u2248 CYP3A7 \u2248 CYP1A1 &lt; CYP4A11 \u2248 CYP2A13 \u2248 CYP2C19 &lt; CYP2B6 \u2248 CYP1A2 \u2248 CYP2C9 &lt; CYP1B1 \u2248 CYP2D6 &lt; CYP2E1 \u2248 CYP2C18, with the greatest decrease (~2-fold) observed in TK6\/CYP3A4 cells. In contrast, five isoforms (CYP2A6, CYP2A7, CYP2C8, CYP3A5, and CYP4B1) showed IC\u2085\u2080 values comparable to controls. To examine further the cytotoxic response, TK6\/CYP vector and TK6\/CYP3A4 cells were treated for 48 h with equitoxic concentrations of clavulanic acid (0.1\u00d7, 0.5\u00d7, and 1.0\u00d7 IC\u2085\u2080). The exposures resulted in a significant concentration-dependent reduction in cell viability, accompanied by increased lactate dehydrogenase release, the induction of apoptosis, G\u2080\/G\u2081 phase arrest, and a concentration-dependent elevation in \u03b3H2AX phosphorylation, indicative of DNA damage. In conclusion, CYP enzymes, especially CYP3A4, likely contribute to clavulanate-induced cytotoxicity, with necrosis, cell cycle disruption, and \u03b3H2AX-associated apoptosis as key cellular responses.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-59728-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:46:16Z","timestamp":1784083576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contribution of cytochrome P450-mediated metabolism to clavulanic acid-induced cytotoxicity in TK6-derived cytochrome P450-overexpressing cell lines"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-5043","authenticated-orcid":false,"given":"Jia-Long","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Beland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"59728_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4065\/74.3.290","volume":"74","author":"AJ Wright","year":"1999","unstructured":"Wright, A. J. The penicillins. Mayo Clin. Proc. 74, 290\u2013307. https:\/\/doi.org\/10.4065\/74.3.290 (1999).","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl 1","key":"59728_CR2","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/jac\/dkh050","volume":"53","author":"AR White","year":"2004","unstructured":"White, A. R. et al. Augmentin\u00ae (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl 1), i3\u2013i20. https:\/\/doi.org\/10.1093\/jac\/dkh050 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"59728_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","volume":"135","author":"N Chalasani","year":"2008","unstructured":"Chalasani, N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135, 1924\u20131934. https:\/\/doi.org\/10.1053\/j.gastro.2008.09.011 (2008).","journal-title":"Gastroenterology"},{"key":"59728_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/ijms17020224","volume":"17","author":"ES Bj\u00f6rnsson","year":"2016","unstructured":"Bj\u00f6rnsson, E. S. Hepatotoxicity by drugs: the most common implicated agents. Int. J. Mol. Sci. 17, 224. https:\/\/doi.org\/10.3390\/ijms17020224 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"59728_CR5","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","volume":"61","author":"AS deLemos","year":"2016","unstructured":"deLemos, A. S. et al. Amoxicillin-Clavulanate-induced liver injury. Dig. Dis. Sci. 61, 2406\u20132416. https:\/\/doi.org\/10.1007\/s10620-016-4121-6 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"59728_CR6","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Amoxicillin-Clavulanate. Updated 20 Oct 2020 (National Institute of Diabetes and Digestive and Kidney Diseases, 2020)."},{"key":"59728_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade, R. J. et al. Drug-induced liver injury. Nat. Rev. Dis. Prim. 5, 58. https:\/\/doi.org\/10.1038\/s41572-019-0105-0 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"59728_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/archinte.1996.00440110099013","volume":"156","author":"LA Garc\u00eda Rodr\u00edguez","year":"1996","unstructured":"Garc\u00eda Rodr\u00edguez, L. A., Stricker, B. H. & Zimmerman, H. J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch. Intern. Med. 156, 1327\u20131332. https:\/\/doi.org\/10.1001\/archinte.1996.00440110099013 (1996).","journal-title":"Arch. Intern. Med."},{"key":"59728_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5694\/j.1326-5377.1992.tb139752.x","volume":"156","author":"GS Hebbard","year":"1992","unstructured":"Hebbard, G. S., Smith, K. G. C., Gibson, P. R. & Bhathal, P. S. Augmentin-induced jaundice with a fatal outcome. Med. J. Aust. 156, 285\u2013286. https:\/\/doi.org\/10.5694\/j.1326-5377.1992.tb139752.x (1992).","journal-title":"Med. J. Aust."},{"key":"59728_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/hepr.12410","volume":"45","author":"C Yazici","year":"2015","unstructured":"Yazici, C., Mutlu, E., Bonkovsky, H. L. & Russo, M. W. Risk factors for severe or fatal drug-induced liver injury from amoxicillin-clavulanic acid. Hepatol. Res. 45, 676\u2013682. https:\/\/doi.org\/10.1111\/hepr.12410 (2015).","journal-title":"Hepatol. Res."},{"key":"59728_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/14740338.6.6.673","volume":"6","author":"SH Hussaini","year":"2007","unstructured":"Hussaini, S. H. & Farrington, E. A. Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf. 6, 673\u2013684. https:\/\/doi.org\/10.1517\/14740338.6.6.673 (2007).","journal-title":"Expert Opin. Drug Saf."},{"key":"59728_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/0960327113512860","volume":"33","author":"DE Amacher","year":"2014","unstructured":"Amacher, D. E. Female gender as a susceptibility factor for drug-induced liver injury. Hum. Exp. Toxicol. 33, 928\u2013939. https:\/\/doi.org\/10.1177\/0960327113512860 (2014).","journal-title":"Hum. Exp. Toxicol."},{"key":"59728_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","volume":"141","author":"MI Lucena","year":"2011","unstructured":"Lucena, M. I. et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338\u2013347. https:\/\/doi.org\/10.1053\/j.gastro.2011.04.001 (2011).","journal-title":"Gastroenterology"},{"key":"59728_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.14218\/JCTH.2015.00007","volume":"3","author":"T Khoury","year":"2015","unstructured":"Khoury, T. et al. Drug induced liver injury: review with a focus on genetic factors, tissue diagnosis, and treatment options. J. Clin. Transl. Hepatol. 3, 99\u2013108. https:\/\/doi.org\/10.14218\/JCTH.2015.00007 (2015).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"59728_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/tx700079z","volume":"21","author":"FP Guengerich","year":"2008","unstructured":"Guengerich, F. P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21, 70\u201383. https:\/\/doi.org\/10.1021\/tx700079z (2008).","journal-title":"Chem. Res. Toxicol."},{"key":"59728_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1021\/tx0002583","volume":"14","author":"FP Guengerich","year":"2001","unstructured":"Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611\u2013650. https:\/\/doi.org\/10.1021\/tx0002583 (2001).","journal-title":"Chem. Res. Toxicol."},{"key":"59728_CR17","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3390\/ijms26052006","volume":"26","author":"BR Maris","year":"2025","unstructured":"Maris, B. R., Grama, A. & Pop, T. L. Drug-induced liver injury\u2014pharmacological spectrum among children. Int. J. Mol. Sci. 26, 2006 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"59728_CR18","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00204-016-1893-6","volume":"91","author":"Y Wu","year":"2017","unstructured":"Wu, Y. et al. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells. Arch. Toxicol. 91, 2405\u20132423. https:\/\/doi.org\/10.1007\/s00204-016-1893-6 (2017).","journal-title":"Arch. Toxicol."},{"key":"59728_CR19","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00204-014-1308-5","volume":"89","author":"Y Wu","year":"2015","unstructured":"Wu, Y., Beland, F. A., Chen, S. & Fang, J.-L. Extracellular signal-regulated kinases 1\/2 and Akt contribute to triclosan-stimulated proliferation of JB6 Cl 41\u20135a cells. Arch. Toxicol. 89, 1297\u20131311. https:\/\/doi.org\/10.1007\/s00204-014-1308-5 (2015).","journal-title":"Arch. Toxicol."},{"key":"59728_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2021.112722","volume":"159","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. In vitro effects of cannabidiol and its main metabolites in mouse and human sertoli cells. Food Chem. Toxicol. 159, 112722. https:\/\/doi.org\/10.1016\/j.fct.2021.112722 (2022).","journal-title":"Food Chem. Toxicol."},{"key":"59728_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/mutage\/gen059","volume":"24","author":"J-L Fang","year":"2009","unstructured":"Fang, J.-L., McGarrity, L. J. & Beland, F. A. Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis 24, 133\u2013141. https:\/\/doi.org\/10.1093\/mutage\/gen059 (2009).","journal-title":"Mutagenesis"},{"key":"59728_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105410","volume":"141","author":"X Li","year":"2023","unstructured":"Li, X. et al. Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays. Regul. Toxicol. Pharmacol. 141, 105410. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105410 (2023).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"59728_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-022-01116-3","volume":"61","author":"FM Keij","year":"2022","unstructured":"Keij, F. M. et al. Pharmacokinetics of clavulanic acid in the pediatric population: a systematic literature review. Clin. Pharmacokinet. 61, 637\u2013653. https:\/\/doi.org\/10.1007\/s40262-022-01116-3 (2022).","journal-title":"Clin. Pharmacokinet."},{"key":"59728_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0267-6605(94)90116-3","volume":"16","author":"M Allen","year":"1994","unstructured":"Allen, M., Millett, P., Dawes, E. & Rushton, N. Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. Clin. Mater. 16, 189\u2013194. https:\/\/doi.org\/10.1016\/0267-6605(94)90116-3 (1994).","journal-title":"Clin. Mater."},{"key":"59728_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mrgentox.2016.06.009","volume":"808","author":"U-K Shah","year":"2016","unstructured":"Shah, U.-K. et al. A comparison of the genotoxicity of benzo[a]pyrene in four cell lines with differing metabolic capacity. Mutat. Res. Genet. Toxicol. Environ. Mutagen 808, 8\u201319. https:\/\/doi.org\/10.1016\/j.mrgentox.2016.06.009 (2016).","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen"},{"key":"59728_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/26896583.2022.2044242","volume":"40","author":"X Li","year":"2022","unstructured":"Li, X. et al. The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells. J. Environ. Sci. Health C Toxicol. Carcinog. 40, 106\u2013118. https:\/\/doi.org\/10.1080\/26896583.2022.2044242 (2022).","journal-title":"J. Environ. Sci. Health C Toxicol. Carcinog."},{"key":"59728_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","volume":"45","author":"BK Park","year":"2005","unstructured":"Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M. & Williams, D. P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177\u2013202. https:\/\/doi.org\/10.1146\/annurev.pharmtox.45.120403.100058 (2005).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"59728_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316\u2013323. https:\/\/doi.org\/10.1038\/nature03097 (2004).","journal-title":"Nature"},{"key":"59728_CR29","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858\u20135868. https:\/\/doi.org\/10.1074\/jbc.273.10.5858 (1998).","journal-title":"J. Biol. Chem."},{"key":"59728_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nrc2523","volume":"8","author":"WM Bonner","year":"2008","unstructured":"Bonner, W. M. et al. \u03b3H2AX and cancer. Nat. Rev. Cancer 8, 957\u2013967. https:\/\/doi.org\/10.1038\/nrc2523 (2008).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59728-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59728-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59728-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:02:07Z","timestamp":1792065727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59728-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59728"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59728-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32365"}}